| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | David F Stern | |
| P2860 | cites work | An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor | Q24293598 |
| The ERBB4/HER4 intracellular domain 4ICD is a BH3-only protein promoting apoptosis of breast cancer cells | Q24293729 | ||
| The intracellular domain of ErbB4 induces differentiation of mammary epithelial cells | Q24296970 | ||
| Mechanism of activation and inhibition of the HER4/ErbB4 kinase | Q24310089 | ||
| WW domain-containing proteins, WWOX and YAP, compete for interaction with ErbB-4 and modulate its transcriptional function | Q24312031 | ||
| Key stages in mammary gland development: the cues that regulate ductal branching morphogenesis | Q24541517 | ||
| Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3 | Q24633878 | ||
| Mammary ductal morphogenesis requires paracrine activation of stromal EGFR via ADAM17-dependent shedding of epithelial amphiregulin | Q24646364 | ||
| AKT/PKB signaling: navigating downstream | Q24657857 | ||
| The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation | Q24678674 | ||
| Outcome and human epidermal growth factor receptor (HER) 1-4 status in invasive breast carcinomas with proliferation indices evaluated by bromodeoxyuridine labelling | Q24794988 | ||
| PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. | Q27824819 | ||
| Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer | Q27824847 | ||
| MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling | Q27851406 | ||
| A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer | Q27851414 | ||
| Untangling the ErbB signalling network | Q27860884 | ||
| gamma -Secretase cleavage and nuclear localization of ErbB-4 receptor tyrosine kinase | Q28202328 | ||
| An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors | Q28207289 | ||
| Presenilin-dependent ErbB4 nuclear signaling regulates the timing of astrogenesis in the developing brain | Q28266755 | ||
| Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways | Q28274882 | ||
| Role for HER2/neu and HER3 in fulvestrant-resistant breast cancer | Q28281901 | ||
| Identification of the scaramanga gene implicates Neuregulin3 in mammary gland specification | Q28511622 | ||
| Targeted inactivation of the EGF and amphiregulin genes reveals distinct roles for EGF receptor ligands in mouse mammary gland development | Q28586880 | ||
| ErbB4 signaling in the mammary gland is required for lobuloalveolar development and Stat5 activation during lactation | Q28594099 | ||
| The cellular response to neuregulins is governed by complex interactions of the erbB receptor family | Q28609130 | ||
| Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions | Q28609149 | ||
| Activation of ErbB4 by the bifunctional epidermal growth factor family hormone epiregulin is regulated by ErbB2 | Q28609160 | ||
| Dynamic expression and activation of ERBB receptors in the developing mouse mammary gland | Q47849375 | ||
| Gene targeting of ErbB3 using a Cre-mediated unidirectional DNA inversion strategy. | Q50714525 | ||
| Activation and function of the epidermal growth factor receptor and erbB-2 during mammary gland morphogenesis. | Q53430753 | ||
| EGFR family expression in breast carcinomas. c-erbB-2 and c-erbB-4 receptors have different effects on survival. | Q53810400 | ||
| Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status | Q57217085 | ||
| Heregulin induces in vivo proliferation and differentiation of mammary epithelium into secretory lobuloalveoli | Q71647189 | ||
| Downregulation of erbB3 abrogates erbB2-mediated tamoxifen resistance in breast cancer cells | Q79696543 | ||
| ErbB-4 s80 intracellular domain abrogates ETO2-dependent transcriptional repression | Q79827702 | ||
| Gene copy numbers of HER family in breast cancer | Q80695489 | ||
| ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer | Q28678776 | ||
| Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer | Q29616112 | ||
| ERBB receptors and cancer: the complexity of targeted inhibitors | Q29619520 | ||
| The E3 ligase Aip4/Itch ubiquitinates and targets ErbB-4 for degradation | Q33282972 | ||
| EGFR associated expression profiles vary with breast tumor subtype | Q33292502 | ||
| Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer | Q33890758 | ||
| Muc4/sialomucin complex, the intramembrane ErbB2 ligand, in cancer and epithelia: to protect and to survive | Q34137381 | ||
| MUC1 is a novel regulator of ErbB1 receptor trafficking | Q34571022 | ||
| Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma | Q34655394 | ||
| ErbB/HER ligands in human breast cancer, and relationships with their receptors, the bio-pathological features and prognosis | Q34706896 | ||
| ErbBs in mammary development | Q35089320 | ||
| Neural and mammary gland defects in ErbB4 knockout mice genetically rescued from embryonic lethality | Q35167885 | ||
| Type 1 growth factor receptor expression in node positive breast cancer: adverse prognostic significance of c-erbB-4 | Q35586732 | ||
| EGFR signal transactivation in cancer cells | Q35594162 | ||
| Heregulin beta1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells | Q36393289 | ||
| Transphosphorylation of kinase-dead HER3 and breast cancer progression: a new standpoint or an old concept revisited? | Q36458755 | ||
| Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients | Q36643014 | ||
| A new mutational AKTivation in the PI3K pathway | Q36907930 | ||
| p185, a product of the neu proto-oncogene, is a receptorlike protein associated with tyrosine kinase activity | Q36914246 | ||
| The role of ErbB3 and its binding partners in breast cancer progression and resistance to hormone and tyrosine kinase directed therapies | Q37006174 | ||
| The efficacy of Herceptin therapies is influenced by the expression of other erbB receptors, their ligands and the activation of downstream signalling proteins | Q37355431 | ||
| ErbB2 is required for ductal morphogenesis of the mammary gland | Q37704948 | ||
| Co-targeting insulin-like growth factor I receptor and HER2: dramatic effects of HER2 inhibitors on nonoverexpressing breast cancer | Q40006210 | ||
| Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network | Q40093663 | ||
| Breast cancer expressing the activated HER2/neu is sensitive to gefitinib in vitro and in vivo and acquires resistance through a novel point mutation in the HER2/neu | Q40105474 | ||
| Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells | Q40344963 | ||
| Secretase-dependent tyrosine phosphorylation of Mdm2 by the ErbB-4 intracellular domain fragment | Q40403940 | ||
| Presenilin-dependent gamma-secretase processing regulates multiple ERBB4/HER4 activities. | Q40450911 | ||
| Cleavable ErbB4 isoform in estrogen receptor-regulated growth of breast cancer cells. | Q40453819 | ||
| Quantitative analysis of HER2-mediated effects on HER2 and epidermal growth factor receptor endocytosis: distribution of homo- and heterodimers depends on relative HER2 levels | Q40657210 | ||
| Heregulin stimulates mitogenesis and phosphatidylinositol 3-kinase in mouse fibroblasts transfected with erbB2/neu and erbB3. | Q41358077 | ||
| Specificity within the EGF family/ErbB receptor family signaling network | Q41721612 | ||
| The basal subtype of breast carcinomas may represent the group of breast tumors that could benefit from EGFR-targeted therapies | Q42503975 | ||
| Expression of dominant-negative ErbB2 in the mammary gland of transgenic mice reveals a role in lobuloalveolar development and lactation | Q42814150 | ||
| Prognostic value of ERBB family mRNA expression in breast carcinomas | Q43461671 | ||
| Heregulin-dependent translocation and hyperphosphorylation of ErbB-2. | Q43663421 | ||
| c-erbB-4/HER4: friend or foe? | Q44503041 | ||
| Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer | Q44503047 | ||
| Impaired differentiation and lactational failure of Erbb4-deficient mammary glands identify ERBB4 as an obligate mediator of STAT5. | Q44572861 | ||
| Molecular mechanisms underlying IGF-I-induced attenuation of the growth-inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells | Q44675816 | ||
| Targeted disruption of ErbB2/Neu in the mammary epithelium results in impaired ductal outgrowth | Q45174160 | ||
| Signaling through the stromal epidermal growth factor receptor is necessary for mammary ductal development. | Q46015486 | ||
| Absence of HER4 expression predicts recurrence of ductal carcinoma in situ of the breast | Q46402523 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | breast cancer | Q128581 |
| P304 | page(s) | 215-223 | |
| P577 | publication date | 2008-05-03 | |
| P1433 | published in | Journal of Mammary Gland Biology and Neoplasia | Q15724460 |
| P1476 | title | ERBB3/HER3 and ERBB2/HER2 duet in mammary development and breast cancer | |
| P478 | volume | 13 |
| Q47158524 | A comprehensive review of heregulins, HER3, and HER4 as potential therapeutic targets in cancer |
| Q35682599 | A critical role for HER3 in HER2-amplified and non-amplified breast cancers: function of a kinase-dead RTK. |
| Q35111697 | A multiscale modeling approach to investigate molecular mechanisms of pseudokinase activation and drug resistance in the HER3/ErbB3 receptor tyrosine kinase signaling network |
| Q39281011 | ADAM-17: a novel therapeutic target for triple negative breast cancer |
| Q38697661 | AXIN1 protects against testicular germ cell tumors via the PI3K/AKT/mTOR signaling pathway |
| Q33891230 | Activation of HER3 interferes with antitumor effects of Axl receptor tyrosine kinase inhibitors: suggestion of combination therapy. |
| Q94596287 | Altered Expression of Three EGFR Posttranslational Regulators MDGI, MIG6, and EIG121 in Invasive Breast Carcinomas |
| Q37588287 | Characterization of a P-Rex1 gene signature in breast cancer cells |
| Q39638952 | Characterization of hybrid cells derived from spontaneous fusion events between breast epithelial cells exhibiting stem-like characteristics and breast cancer cells |
| Q33739262 | Co-expression of HER2 and HER3 receptor tyrosine kinases enhances invasion of breast cells via stimulation of interleukin-8 autocrine secretion |
| Q27323236 | Coarse-grained molecular simulation of epidermal growth factor receptor protein tyrosine kinase multi-site self-phosphorylation |
| Q37248165 | Darpp-32 and its truncated variant t-Darpp have antagonistic effects on breast cancer cell growth and herceptin resistance |
| Q36437261 | Decreased LRIG1 in fulvestrant-treated luminal breast cancer cells permits ErbB3 upregulation and increased growth |
| Q35029586 | During hormone depletion or tamoxifen treatment of breast cancer cells the estrogen receptor apoprotein supports cell cycling through the retinoic acid receptor α1 apoprotein. |
| Q34349106 | E3 ubiquitin ligases in ErbB receptor quantity control |
| Q34348232 | EGFR signaling in breast cancer: bad to the bone. |
| Q34356008 | EGFs and ERBBs—Brief history and prospects |
| Q33772914 | ERBB3: A potential serum biomarker for early detection and therapeutic target for devil facial tumour 1 (DFT1) |
| Q37885731 | Emerging therapeutic targets in schwannomas and other merlin-deficient tumors |
| Q38341899 | Endocrine hormones and local signals during the development of the mouse mammary gland. |
| Q37517706 | Enhanced PI3K p110α signaling confers acquired lapatinib resistance that can be effectively reversed by a p110α-selective PI3K inhibitor |
| Q35479646 | ErbB3 ablation impairs PI3K/Akt-dependent mammary tumorigenesis |
| Q37200831 | ErbB3 downregulation enhances luminal breast tumor response to antiestrogens |
| Q41467086 | ErbB3 drives mammary epithelial survival and differentiation during pregnancy and lactation |
| Q37131318 | ErbB3 is required for ductal morphogenesis in the mouse mammary gland |
| Q38089837 | Evaluation of HER2 in breast cancer: reality and expectations. |
| Q43912153 | Fatty acid synthase affects expression of ErbB receptors in epithelial to mesenchymal transition of breast cancer cells and invasive ductal carcinoma |
| Q28740473 | Gefitinib induces epidermal growth factor receptor dimers which alters the interaction characteristics with ¹²⁵I-EGF |
| Q64894479 | HER-3 Knocking Down Induces G2/M Arrest in Gastric Cancer Cells. |
| Q34121631 | HER2/ErbB2-induced breast cancer cell migration and invasion require p120 catenin activation of Rac1 and Cdc42 |
| Q37407344 | HER2/HER3 regulates extracellular acidification and cell migration through MTK1 (MEKK4). |
| Q36957145 | HER3 is required for HER2-induced preneoplastic changes to the breast epithelium and tumor formation. |
| Q34117767 | Heregulin β-1 induces loss of cell-cell contact and enhances expression of MUC1 at the cell surface in HCC2998 and MKN45-1 cells |
| Q38770505 | Heregulin/ErbB3 Signaling Enhances CXCR4-Driven Rac1 Activation and Breast Cancer Cell Motility via Hypoxia-Inducible Factor 1α. |
| Q37718269 | Human epidermal growth factor receptor 4 (HER4) is a favorable prognostic marker of breast cancer: a systematic review and meta-analysis |
| Q38382793 | Immunohistochemical Assessment of HER3 Expression in Odontogenic Cysts |
| Q47112669 | Increased expression of miR-155 and miR-222 is associated with lymph node positive status |
| Q37690877 | Localisation Microscopy of Breast Epithelial ErbB-2 Receptors and Gap Junctions: Trafficking after γ-Irradiation, Neuregulin-1β, and Trastuzumab Application. |
| Q34014659 | Mammary gland growth factors: roles in normal development and in cancer |
| Q35683544 | Mammary gland specific expression of Brk/PTK6 promotes delayed involution and tumor formation associated with activation of p38 MAPK. |
| Q38981333 | Membrane Protein Quantity Control at the Endoplasmic Reticulum |
| Q27318931 | Met receptor acts uniquely for survival and morphogenesis of EGFR-dependent normal mammary epithelial and cancer cells |
| Q35379924 | Microbead arrays for the analysis of ErbB receptor tyrosine kinase activation and dimerization in breast cancer cells |
| Q38771799 | Molecular Profiling and Malignant Behavior Define Two Rat Mammary Tumor Cell Lines as a Relevant Experimental Model |
| Q33559178 | Molecular Signaling of Progesterone, Growth Hormone, Wnt, and HER in Mammary Glands of Dogs, Rodents, and Humans: New Treatment Target Identification |
| Q37854682 | Molecular regulators of pubertal mammary gland development |
| Q37653334 | Oligomerization of the Nrdp1 E3 ubiquitin ligase is necessary for efficient autoubiquitination but not ErbB3 ubiquitination |
| Q33809397 | Overexpression of c-erbB2 is a negative prognostic factor in anaplastic astrocytomas |
| Q41628138 | PDK1-mTOR signaling pathway inhibitors reduce cell proliferation in MK2206 resistant neuroblastoma cells |
| Q36116250 | Peptide vaccines and targeting HER and VEGF proteins may offer a potentially new paradigm in cancer immunotherapy |
| Q35174240 | Perhexiline promotes HER3 ablation through receptor internalization and inhibits tumor growth |
| Q37148772 | Pertuzumab Increases 17-AAG-Induced Degradation of ErbB2, and This Effect Is Further Increased by Combining Pertuzumab with Trastuzumab |
| Q34121278 | Post-transcriptional mechanisms contribute to the suppression of the ErbB3 negative regulator protein Nrdp1 in mammary tumors |
| Q36895558 | Posttranslational protein knockdown coupled to receptor tyrosine kinase activation with phosphoPROTACs |
| Q37331776 | Profile of estrogen-responsive genes in an estrogen-specific mammary gland outgrowth model |
| Q46610690 | Prognostic value of immunohistochemical expression profile of epidermal growth factor receptor in urothelial bladder cancer |
| Q38802182 | Pubertal Mammary Gland Development: Elucidation of In Vivo Morphogenesis Using Murine Models |
| Q35096647 | Quantity control of the ErbB3 receptor tyrosine kinase at the endoplasmic reticulum |
| Q37153625 | Role of ErbB4 in breast cancer |
| Q41876318 | Saccharomyces boulardii inhibits EGF receptor signaling and intestinal tumor growth in Apc(min) mice |
| Q26860299 | Screening for Chemical Contributions to Breast Cancer Risk: A Case Study for Chemical Safety Evaluation |
| Q37316604 | Signal integration: a framework for understanding the efficacy of therapeutics targeting the human EGFR family |
| Q36919811 | Sorafenib and pemetrexed toxicity in cancer cells is mediated via SRC-ERK signaling |
| Q33769117 | Synthesis and biochemical characterization of EGF receptor in a water-soluble membrane model system |
| Q46087491 | Targeting protein quality control pathways in breast cancer |
| Q28910204 | The ER structural protein Rtn4A stabilizes and enhances signaling through the receptor tyrosine kinase ErbB3 |
| Q28073335 | The Under-Appreciated Promiscuity of the Epidermal Growth Factor Receptor Family |
| Q37312071 | The anti-erbB3 antibody MM-121/SAR256212 in combination with trastuzumab exerts potent antitumor activity against trastuzumab-resistant breast cancer cells |
| Q37602303 | The epidermal growth factor system of ligands and receptors in cancer |
| Q33584305 | The normal breast microenvironment of premenopausal women differentially influences the behavior of breast cancer cells in vitro and in vivo |
| Q51557964 | The role of estrogen receptors, erbB receptors, vascular endothelial growth factor and its receptors, and vascular endothelial growth inhibitor in the development of the rat mammary gland. |
| Q36396579 | The role of microRNAs in breast cancer migration, invasion and metastasis |
| Q37690272 | Therapeutic targeting of erbB3 with MM-121/SAR256212 enhances antitumor activity of paclitaxel against erbB2-overexpressing breast cancer. |
| Q33390756 | Transcriptome analysis of mammary epithelial subpopulations identifies novel determinants of lineage commitment and cell fate |
| Q90118062 | Transcriptomic and computational analysis identified LPA metabolism, KLHL14 and KCNE3 as novel regulators of Epithelial-Mesenchymal Transition |
| Q38259322 | Triple-negative breast cancer: investigating potential molecular therapeutic target |
| Q35172558 | Urothelial carcinomas: a focus on human epidermal receptors signaling |
| Q33867525 | Use of the ODD-luciferase transgene for the non-invasive imaging of spontaneous tumors in mice. |
| Q38883916 | Validation of an in vitro model of erbB2(+) cancer cell redirection |
| Q34273176 | miR-143 and miR-145 synergistically regulate ERBB3 to suppress cell proliferation and invasion in breast cancer |
Search more.